• Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study

    Tuesday October 20th 2020

  • Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

    Friday October 16th 2020

  • Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

    Wednesday October 14th 2020

  • Phase 2B/3 Trial shows efficacy of Filgotinib for the induction and maintenance of remission in moderately and severely active Ulcerative Colitis

    Tuesday October 13th 2020

  • argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial

    Monday October 5th 2020

  • Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

    Wednesday September 30th 2020

  • Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

    Tuesday September 29th 2020

  • Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

    Thursday September 24th 2020

  • Your news here?

  • Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study

    Tuesday September 22nd 2020

  • Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients

    Friday September 11th 2020

  • Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Tuesday September 1st 2020


Strategic Partners